Abstract:AbstractOral omega-3 ethylester concentrate (omega-3 EEC) [Omacor®; Lovaza™] is indicated as an adjuvant therapy in adult patients for secondary prevention post-myocardial infarction (MI) and the treatment of hypertriglyceridaemia in the majority of European countries, and for the treatment of hypertriglyceridaemia (serum triglyceride levels ≥5.6mmol/L [≥500mg/dL]) in the US. Each 1000 mg capsule of omega-3 EEC consists of 460 mg of ethyl eicosapentaenoic acid and 380 mg of ethyl docosahexaenoic acid.The addition of omega-3 EEC 1000 mg/day to standard medical therapy in the GISSI-Prevenzione study provided secondary prevention benefits in post-MI adult patients. The benefits were attributable to reductions in death and cardiovascular death (including sudden death). Additional data examining the extent and mechanisms of the cardiovascular benefit conferred by omega-3 EEC in secondary prevention would be useful. As an adjunct to diet, monotherapy with omega-3 EEC 4000 mg/day significantly reduced triglyceride levels in patients with hypertriglyceridaemia, although limited data suggest it was less effective than gemfibrozil. In addition, omega-3 EEC 4000 mg/day plus simvastatin or atorvastatin reduced triglyceride, non-high-density lipoprotein cholesterol (non-HDL-C) and/or very-low-density lipoprotein cholesterol (VLDL-C) levels to a significantly greater extent than placebo plus simvastatin or atorvastatin. Omega-3 EEC was generally well tolerated both as secondary prevention post-MI and in the treatment of hypertriglyceridaemia. Thus, omega-3 EEC is a useful option both in secondary prevention post-MI and the treatment of hypertriglyceridaemia.Pharmacological PropertiesThe proposed mechanisms of action for the triglyceride-lowering effects observed with omega-3 EEC are inhibition of acyl CoA:1,2-diacylglycerol acyltransferase and elevation in hepatic peroxisomal β-oxidation, with upregulation of fatty acid metabolism in the liver. Omega-3 fatty acids may also inhibit the secretion of triglyceride-rich VLDL-C, increase the removal of triglycerides from circulating VLDL and chylomicron particles via the upregulation of enzymes such as lipoprotein lipase, and affect other nuclear receptors involved in the modulation of triglyceride levels.Various mechanisms have been proposed to explain the secondary preventive effect of omega-3 EEC in patients with recent MI, including cardiovascular effects, effects on thrombosis and haemostasis and antiatherogenic and anti-inflammatory effects. The cardiovascular effects include reduced blood pressure and heart rate, and antiarrhythmic effects (proposed mechanisms include increased antiarrhythmic thresholds, effects on ion channels and effects on autonomic balance) and augmentation of autonomic tone, both of which may contribute to the reduced risk of sudden cardiac death seen in patients with recent MI who received omega-3 EEC in the GISSI-Prevenzione study.Antithrombotic effects have also been observed with omega-3 fatty acids, and although omega-3 EEC does not appear to affect bleeding time, patients receiving anticoagulant therapy and omega-3 EEC should be monitored and the anticoagulant dosage adjusted as necessary.The effect of omega-3 EEC on the prevention of restenosis is equivocal; however, the drug may improve plaque stability. Omega-3 EEC appears to reduce the levels of various markers of inflammation, including messenger RNA levels for a number of matrix metalloproteinases and intercellular adhesion molecule-1, the gene expression of platelet-derived growth factor-A and -B, endotoxin-stimulated tumour necrosis factor-α production and reduce soluble E-selectin levels. In general, omega-3 fatty acids did not affect C-reactive protein or interleukin-6 levels.Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are absorbed following their oral administration as ethylesters to healthy volunteers and patients with hypertriglyceridaemia, with subsequent dose-dependent elevations in plasma phospholipid EPA and DHA content. Age (<49 vs ≥49 years) did not affect the uptake of EPA and DHA into serum phospholipids in omega-3 EEC recipients, although the uptake of EPA in serum phospholipids tended to be greater in women than in men.Therapeutic EfficacyOral omega-3 EEC 1000 mg/day, as an adjuvant therapy to standard treatment (e.g. ACE inhibitors, antiplatelet agents, β-adrenergic receptor antagonists, HMG-CoA reductase inhibitors), demonstrated a secondary preventive effect in patients with recent (<3 months) MI in the 42-month, randomized, nonblind (endpoints validated by a blinded assessment committee), multicentre GISSI-Prevenzione study. Omega-3 EEC-based therapy (omega-3 EEC 1000 mg/day and omega-3 EEC 1000 mg/day plus tocopherol groups) significantly reduced the risk of a primary composite efficacy endpoint (death plus nonfatal MI plus nonfatal stroke) and various secondary or other endpoints (including death, cardiovascular death and sudden death) versus non-omega-3 EEC-based therapy (the tocopherol monotherapy and no treatment groups) in a two-way analysis of data. Significant reductions versus control in the risk of death plus nonfatal MI plus nonfatal stroke with omega-3 EEC monotherapy and omega-3 EEC plus tocopherol therapy, and in the risk of cardiovascular death plus nonfatal MI plus nonfatal stroke with omega-3 EEC monotherapy were also demonstrated in a four-way analysis. For the most part, omega-3 EEC therapy, with or without tocopherol, and tocopherol monotherapy were significantly more effective than no treatment in terms of secondary endpoints, with significant reductions (of 20–45%) in the relative risk of various secondary endpoints observed across all three active therapy groups versus no treatment.According to preliminary data from the 12-month, randomized, double-blind, placebo-controlled, multicentre OMEGA study, no significant difference in the incidence of sudden cardiac death (primary endpoint) and the various secondary endpoints was observed between the omega-3 EEC and placebo groups in patients with recent (3–14 days) MI. Of note, the observed incidence of sudden cardiac death in both the omega-3 EEC and placebo groups was lower than anticipated.Data from a limited number of studies indicated that omega-3 EEC plus standard therapy was predicted to be cost effective in secondary prevention post-MI relative to standard therapy in terms of cost per life-year or quality-adjusted life-year gained.Oral omega-3 EEC 4000 mg/day, as monotherapy or in combination with simvastatin or atorvastatin, was generally effective as an adjunct to diet in the treatment of hypertriglyceridaemia in adult patients. For the most part, omega-3 EEC monotherapy demonstrated significantly greater reductions from baseline than placebo in triglyceride, total cholesterol and VLDL-C levels, and significantly greater elevations from baseline in HDL-C levels in a well designed study. In contrast, significant elevations in low-density lipoprotein cholesterol levels were observed in omega-3 EEC monotherapy versus placebo recipients. Limited data suggest oral gemfibrozil was associated with significantly greater reductions in serum triglyceride levels (primary endpoint) and significantly greater increases in HDL-C levels than omega-3 EEC monotherapy. However, no significant differences in total cholesterol and VLDL-C levels were observed between the two treatment groups. In general, omega-3 EEC plus simvastatin was an effective lipid-modifying therapy in patients with hypertriglyceridaemia, inducing significantly greater reductions from baseline in triglyceride and VLDL-C levels than placebo plus simvastatin in two well designed clinical studies. In one study, the primary endpoint of non-HDL-C levels was reduced by a significantly greater extent with omega-3 EEC plus simvastatin than with placebo plus simvastatin. For the most part, improvements in the lipid profiles of patients with hypertriglyceridaemia observed in the 24-week, double-blind phase of one study were sustained with continued omega-3 EEC plus simvastatin therapy in the 24-week, noncomparative extension phase. Preliminary data indicated that omega-3 EEC plus atorvastatin was associated with significantly greater reductions from baseline in non-HDL-C (primary endpoint), total cholesterol, triglyceride and VLDL-C levels and significantly greater improvements from baseline in HDL-C levels, than placebo plus atorvastatin in patients with hypertriglyceridaemia.TolerabilityOral omega-3 EEC was generally well tolerated by adult patients participating in five randomized, multicentre studies of up to 42 months’ duration in secondary prevention post-MI and the treatment of hypertriglyceridaemia. Treatment-emergent adverse events associated with omega-3 EEC were generally gastrointestinal in nature and mild or minor in intensity. In the GISSI-Prevenzione study, treatment-emergent gastrointestinal disturbances and nausea were observed in 4.9% and 1.4% of patients receiving omega-3 EEC-based therapy, and in 2.9% and 0.4% of patients receiving tocopherol-based therapy (tocopherol monotherapy and omega-3 EEC plus tocopherol groups). Therapy stopped because of adverse events in 3.8% and 2.1% of patients in the respective treatment groups.

Vhrm_a_325217 571..580

Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial

The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study

Change Of Plasma Metabolites In Response To Omega-3 Fatty Acids In Chinese Patients With Type 2 Diabetes: A Double-Blinded Randomized Controlled Trial

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study

Effects of n-3 fatty acid supplements on cardiometabolic profiles in hypertensive patients with abdominal obesity in Inner Mongolia: a randomized controlled trial.

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia

Omega-3 Ethylester Concentrate

Serum metabolomics profiles in response to n-3 fatty acids in Chinese patients with type 2 diabetes: a double-blind randomised controlled trial

Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia

Changes of urine metabolites in response to n-3 fatty acid supplements and their correlation with metabolic risk factors in patients with type 2 diabetes.

Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia

Icosapent Ethyl Therapy for Very High Triglyceride Levels: a 12-Week, Multi-Center, Placebo-Controlled, Randomized, Double-Blinded, Phase III Clinical Trial in China

Elevated Serum Phosphatidylcholine (16:1/22:6) Levels Promoted by Fish Oil and Vitamin D3 Are Highly Correlated with Biomarkers of Non-Alcoholic Fatty Liver Disease in Chinese Subjects.

Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia

Use of Digital Technology Tools to Characterize Adherence to Prescription-Grade Omega-3 Polyunsaturated Fatty Acid Therapy in Postmyocardial or Hypertriglyceridemic Patients in the DIAPAsOn Study: Prospective Observational Study

Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification: A sixteen-week randomized intervention trial

Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus® and placebo